Comparative Pharmacology
Head-to-head clinical analysis: BRENZAVVY versus INVOKAMET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRENZAVVY versus INVOKAMET.
BRENZAVVY vs INVOKAMET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brenzavvy (bexagliflozin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. It inhibits SGLT2 in the proximal renal tubule, reducing glucose reabsorption and increasing urinary glucose excretion, thereby lowering blood glucose levels. It also promotes osmotic diuresis and may improve cardiovascular and renal outcomes through hemodynamic and metabolic effects.
INVOKAMET is a combination of canagliflozin, an SGLT2 inhibitor, and metformin, a biguanide. Canagliflozin inhibits sodium-glucose cotransporter 2 in the renal proximal tubules, reducing glucose reabsorption and increasing urinary glucose excretion. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity.
Recommended dose: 1 tablet (200 mg finerenone) orally once daily.
Oral: Starting dose: 5 mg canagliflozin/500 mg metformin hydrochloride extended-release twice daily; titrate based on efficacy and tolerability, maximum 150 mg/1000 mg twice daily.
None Documented
None Documented
The terminal elimination half-life is approximately 12-15 hours in patients with normal renal function, supporting once-daily dosing.
Canagliflozin: 10–13 hours (multiple dosing); Metformin: 6.2 hours (plasma). Accumulation occurs in renal impairment.
Approximately 65% of the dose is excreted renally as unchanged drug, and about 35% is eliminated via biliary/fecal routes as metabolites.
Canagliflozin (SGLT2 inhibitor): ~33% renal (1% unchanged, ~33% as glucuronide metabolites), ~52% fecal. Metformin (biguanide): 90% renal unchanged via tubular secretion.
Category C
Category C
SGLT2 Inhibitor
SGLT2 Inhibitor / Biguanide Combination